Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Markers implicated in fatal side effects of schizophrenia drug identified
January 25th, 2005
Genaissance Pharmaceuticals, Inc., (GNSC) announced results from its CARING (clozapine and agranulocytosis relationships investigated by genetics) study, reporting the discovery of genetic markers that the company believes predict who is at risk of developing clozapine-induced agranulocytosis, a life-threatening decrease of white blood cells that requires frequent blood testing of patients. The company said the findings may apply to other drugs that also affect white blood cell counts. "In light of recent drug withdrawals and labeling restrictions due to rare but serious adverse drug events, these results underscore the potential of pharmacogenetics...
Source: Life Science Weekly (2005-01-25)
|
